Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
Published Online: 2021-06-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Andrea Necchi•Arjun V Balar•Bradley McGregor•Daniel P Petrylak•David I Quinn•Elisabeth I Heath•Evan Y Yu•Jae-Lyun Lee•Janet Trowbridge•Jonathan E Rosenberg•Joyce Steinberg•Mark N Stein•Mary Campbell•Michael R Harrison•Michiel S van der Heijden•Peter H O'Donnell•Se Hoon Park•Shang-Ying Liang•Takahiro Kojima•Yohann Loriot
